Table 1 Demographic and clinical characteristics of AML patients and healthy controls.

From: Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

Demographic characteristics

Discovery Population (n = 2027)

338 AML cases and 1689 healthy controls

Replication Population (n = 2104)

316 AML cases and 1788 healthy controls

Overall Population (n = 4131)

654 AML cases and 3477 healthy controls

AML cases

Age (years)

55.19 ± 15.12

56.91 ± 17.25

56.02 ± 16.20

Sex ratio (male/female)

1.13 (179/159)

1.29 (178/138)

1.20 (356/297)

Country of origin

   

Spain

257

97

354

Germany

26

74

100

Italy

145

145

Austria

55

55

Presentation

de novo (n, %)

324 (95.86)

285 (90.19)

609 (93.12)

Secondary (n, %)

14 (04.14)

31 (09.81)

45 (06.88)

Healthy controls

Age (years)*

56.10 ± 9.55

42.76 ± 11.76

49.57 ± 11.33

Sex ratio (male/female)

1.07 (871/818)

0.91 (848/937)

0.98 (1719/1754)

 Country of origin

Spain

667

507

1174

Germany

1000

1087

2087

Italy

194

194

Austria

22

22

  1. Data are means ± standard deviation or percentage (%). A set of 99 patients (39 and 61 from the discovery and replication cohorts, respectively) could not be classified according to the FAB classification.
  2. AML acute myeloid leukaemia
  3. *Age was not available in a set of German controls included in the discovery (n = 1000) and replication cohorts (n = 1068).